Summary

An extended course of thromboprophylaxis with apixaban did not reduce the risk of venous thromboembolism (VTE, which consists of pulmonary embolism and deep venous thrombosis) and VTE-related death in medically ill patients compared with a shorter course of enoxaparin, according to findings from the Apixaban Dosing to Optimize Protection from Thrombosis trial [ADOPT; NCT00457002].